Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Buy” by Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have received an average rating of “Buy” from the twenty-two research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have covered the stock in the last year is $181.33.

Several equities analysts have recently commented on SRPT shares. Royal Bank of Canada restated an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research report on Monday, October 21st. They issued a “buy” rating and a $165.00 target price for the company. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Raymond James restated an “outperform” rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Finally, Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $117.84 on Tuesday. The company has a quick ratio of 3.19, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $11.26 billion, a P/E ratio of 94.27 and a beta of 0.81. Sarepta Therapeutics has a 12-month low of $76.61 and a 12-month high of $173.25. The firm has a 50-day moving average price of $125.56 and a two-hundred day moving average price of $132.90.

Insider Buying and Selling

In related news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently made changes to their positions in SRPT. Farallon Capital Management LLC lifted its holdings in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after acquiring an additional 1,243,427 shares during the last quarter. Principal Financial Group Inc. raised its position in Sarepta Therapeutics by 693.7% in the 2nd quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company’s stock worth $57,356,000 after purchasing an additional 317,277 shares during the period. Canada Pension Plan Investment Board raised its position in Sarepta Therapeutics by 2,257.8% in the 1st quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company’s stock worth $31,135,000 after purchasing an additional 230,300 shares during the period. Rhumbline Advisers raised its position in Sarepta Therapeutics by 146.3% in the 2nd quarter. Rhumbline Advisers now owns 270,941 shares of the biotechnology company’s stock worth $42,809,000 after purchasing an additional 160,942 shares during the period. Finally, Blair William & Co. IL raised its position in Sarepta Therapeutics by 303.7% in the 2nd quarter. Blair William & Co. IL now owns 174,282 shares of the biotechnology company’s stock worth $27,537,000 after purchasing an additional 131,112 shares during the period. 86.68% of the stock is owned by institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.